A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Despite randomized controlled trials demonstrating mortality reduction, many studies have documented persistent low rates of prescription of angiotensinconverting enzyme inhibitors (ACE-I) in patients with heart failures; the reasons for this pattern remain poorly defined. In addition, some authors have argued that the results of carefully controlled clinical trials do not translate well into the uncontrolled world of clinical practice, and the mortality benefits of ACE-I may not extend intodoi:10.1001/archinte.158.18.2024 pmid:9778202 fatcat:zbyedfrbe5artkqsmsglnfdg3u